Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000769993-25-000401
Filing Date
2025-07-03
Accepted
2025-07-03 12:23:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8719
2 POA13G-27051828_20250627.txt EX-99 5139
  Complete submission text file 0000769993-25-000401.txt   15746
Mailing Address 200 WEST STREET NEW YORK NY 10282
Business Address 200 WEST STREET NEW YORK NY 10282 212-902-1000
GOLDMAN SACHS GROUP INC (Filed by) CIK: 0000886982 (see all company filings)

EIN.: 134019460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91724 | Film No.: 251104496
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)